Silo Pharma Advances Clinical Study Analyzing Effects of Psilocybin on Inflammation
Parkinson’s disease, bipolar disorder, and chronic pain targeted in study
Study aims to support psilocybin as a potential therapeutic for inflammatory disorders
Related news for (SILO)
- Small Caps Aim Big as Digital Asset Strategies Spark Momentum
- MoBot’s Stock Market Highlights – 09/23/25 08:00 AM
- Silo Pharma Signs Strategic Agreement with Fireblocks to Advance Crypto Treasury Strategy Acquisition and Security
- 24/7 Market News Snapshot 23 September, 2025 – Silo Pharma, Inc. Common Stock (NASDAQ:SILO)
- Silo Pharma Announces Initial Investment in Ethereum and Solana under Cryptocurrency Treasury Strategy